Akt activation in renal cell carcinoma: Contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

Annals of Oncology

Volumn 16, Issue 6, 2005, Pages 928-933

  Hara, S ^a   Oya, Moto ^a   Mizuno, R ^a   Horiguchi, A ^a   Marumo, K ^a   Murai, M ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; Bad; PTEN; Renal cell carcinoma

Indexed keywords

6 HYDROXYMETHYLINOSITOL 2 2 O METHYL 3 O OCTADECYLCARBONATE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 21344446791     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi182     Document Type: Article

References (18)

1. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435-437.
2. Itoh N, Semba S, Ito M et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94: 3127-3134.
3. Kurose K, Zhou XP, Araki T et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001; 158: 2097-2106.
4. Kanamori Y, Kigawa J, Itamochi H et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7: 892-895.
5. Ringel MD, Hayre N, Saito J et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61: 6105-6111.
6. Horiguchi A, Oya M, Uchida A et al. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 2003; 169: 710-713.
7. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
8. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
9. Sakurada A, Suzuki A, Sato M et al. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 1997; 88: 1025-1028.
10. Cairns P, Evron E, Okami K et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 3215-3218.
11. Alimov A, Li C, Gizatullin R et al. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 1999; 19: 3841-3846.
12. Kondo K, Yao M, Kobayashi K et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91: 219-224.
13. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002; 99: 53-57.
14. Yuan ZQ, Sun M, Feldman RI et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324-2330.
15. Tachibana M, Miyakawa A, Nakashima J et al. Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinoma line KU-19-20. Cell Tissue Res 2000; 301: 353-367.
16. Hu Y, Qiao L, Wang S et al. 3-(Hydroxymethyl)-be earing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 2000; 43: 3045-3051.
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
18. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381-386.